Skip to content

A Study on the Occurrence Time of Grade-B Pancreatic Fistula After Pancreatoduodenectomy

A Study on the Occurrence Time of Clinically Relevant Postoperative Pancreatic Fistula of Grade-B After Pancreatoduodenectomy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05667272
Enrollment
216
Registered
2022-12-28
Start date
2023-02-01
Completion date
2023-05-31
Last updated
2023-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pancreatic Fistula

Keywords

postoperative pancreatic fistula

Brief summary

To confirm the time point of CR-POPF of grade-B that patients with biochemical leak after PD or LPD turned into.

Detailed description

1. To confirm the time point of CR-POPF of grade-B that patients with biochemical leak after PD or LPD turned into. 2. Establishment of risk assessment model for Grade B fistula.

Interventions

OTHERNo intervention

No intervention

Sponsors

Changzhou Second People's Hospital affiliated with Nanjing Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients underwent Pancreatoduodenectomy (PD) or Laparoscopic pancreatoduodenectomy (LPD) surgery. * Surgery performed by the same surgical team.

Exclusion criteria

* PD or LPD combined with another organ resection. * PD or LPD performed due to trauma. * PD or LPD for emergency treatment, such as the rupture and bleeding of tumor. * Palliative resection. * Patients with severe organ dysfunction before surgery. * Patients treated with preoperative neoadjuvant chemotherapy or other treatments (Radiotherapy, targeted immunotherapy, etc.). * Patients with missing data for clinical or radiographic variables.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative complicationsup to postoperative 30 daysPostoperative complications for each patient

Countries

China

Contacts

Primary Contactchunfu zhu, PhD
zcfmlm@njmu.edu.cn+8613961190702

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026